Clinical effect observation of unfractionated heparin versus low molecular weight heparin sodium in preventing venous thromboembolism in lung cancer patients
-
摘要: 目的 探讨普通肝素与低分子肝素钠预防肺癌患者静脉血栓栓塞症(VTE)的疗效差异。 方法 选取96例肺癌患者作为研究对象, 采用随机数表法将其分为2组,各48例。实验组采用低分子肝素钠注射预防VTE, 对照组选用普通肝素预防VTE。对比2组VTE发生率、凝血功能指标和血小板计数(PLT)、动脉血气指标、不良反应发生情况和生存质量评分。 结果 治疗后,实验组VTE发生率为4.17%, 显著低于对照组16.67%(P<0.05); 治疗前后, 2组PLT、纤维蛋白原(FIB)、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)相比,差异均无统计学意义(P>0.05); 治疗后, 2组患者动脉血二氧化碳分压［p(CO2)］、动脉血氧分压［p(O2)］与动脉血氧饱和度(SaO2)均显著高于治疗前(P<0.05), 且实验组p(CO2)、p(O2)、SaO2均显著优于对照组(P<0.05); 2组不良反应发生率比较,差异无统计学意义(P>0.05); 出院时, 2组患者生存质量均显著高于治疗前(P<0.05), 但2组出院时生存质量无显著差异(P>0.05)。 结论 与普通肝素相比,低分子肝素钠预防肺癌患者VTE的效果更显著,对动脉血气指标、凝血功能指标和血小板的影响小,有助于提高患者生存质量。Abstract: Objective To observe efficacy difference of unfractionated heparin versus low molecular weight heparin sodium in preventing venous thromboembolism(VTE)in lung cancer patients. Methods A total of 96 lung cancer patients were enrolled, and were divided into two groups by random number table method. The experimental group(n=48)was treated with low molecular weight heparin sodium to prevent VTE, while the control group(n=48)was treated with unfractionated heparin to prevent VTE. The incidence of VTE, coagulation function indexes and blood platelet count(PLT), blood gas indexes of pulmonary artery, occurrence of adverse reactions and quality of life scores were compared between the two groups. Results After treatment, incidence of VTE in experimental group was lower than that in control group(4.17% vs. 16.67%, P<0.05). There were no significant differences in PLT, fibrinogen(FIB), prothrombin time(PT)or activated partial thromboplastin time(APTT)between the two groups before and after treatment(P>0.05). After treatment, partial pressure of carbon dioxide ［p(CO2)］, blood oxygen partial pressure ［p(O2)］ and arterial oxygen saturation(SaO2)in the experimental group were higher than those in control group(P<0.05), and the experimental group was better than the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). At discharge, quality of life in both groups was higher than that before treatment(P<0.05). There was no difference in quality of life between the two groups at discharge(P>0.05). Conclusion Compared - with unfractionated heparin, low molecular weight heparin sodium has significant efficacy in preventing VTE in lung cancer patients and can promote the survival quality, with less effects on blood gas indexes, coagulation function indexes and blood platelet.
-
-
王燕玲, 何丽, 王燕燕, 等. 非小细胞肺癌合并静脉血栓栓塞症危险因素分析[J]. 中国医学前沿杂志: 电子版, 2017, 9(8): 126-129. Schulman S, Ageno W, Konstantinides S V. Venous thromboembolism: Past, present and future[J]. Thromb Haemost, 2017, 117(7): 1219-1229.
吕国芹. 基于中西医结合骨科静脉血栓栓塞症规范化预防体系的构建[J]. 实用临床医药杂志, 2019, 23(23): 37-39. 张平, 王林娟. 肺腺癌患者PICC置管后静脉血栓形成的危险因素分析[J]. 中国医学前沿杂志: 电子版, 2017, 9(3): 33-36. 李燕, 许秀芳, 吴小艳, 等. 低分子肝素两种皮下注射方法不良反应的对照研究[J]. 介入放射学杂志, 2018, 27(1): 83-86. Bahl V, Hu H M, Henke P K, et al. A validation study of a retrospective venous thromboembolism risk scoring method[J]. Ann Surg, 2010, 251(2): 344-350.
Cella D F, Bonomi A E, Lloyd S R, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung(FACT-L)quality of life instrument[J]. Lung Cancer, 1995, 12(3): 199-220.
乔力松, 许小毛, 杨鹤, 等. 肺癌、消化及泌尿系恶性肿瘤合并静脉血栓栓塞症的临床特点及预后比较[J]. 中华医学杂志, 2018, 98(18): 1403-1407. 洪娇, 程弯弯, 王艳丽, 等. 96例肺腺癌伴发静脉血栓栓塞症危险因素分析[J]. 南京医科大学学报: 自然科学版, 2018, 38(9): 1234-1239. Jones D, Wismayer K, Bozas G, et al. The risk of venous thromboembolism associated with peripherally inserted central catheters in ambulant cancer patients[J]. Thromb J, 2017, 15: 25-28.
Jara-Palomares L, Otero R, Jimenez D, et al. Development of a risk prediction score for occult cancer in patients with VTE[J]. Chest, 2017, 151(3): 564-571.
刘晓媛, 刘玉梅, 邵丽. 不同抗凝方案对不稳定型心绞痛患者PCI围术期抗凝效果分析[J]. 中国医学前沿杂志: 电子版, 2018, 10(3): 98-101. 冉梦晓, 陈辉. 局部枸橼酸抗凝对老年终末期肾脏病维持性血液透析患者肾功能、凝血功能及体外循环凝血的影响分析[J]. 中国医学前沿杂志: 电子版, 2019, 11(4): 49-52. 阿比旦·阿不力孜, 殷莉, 王丽, 等. 老年腰椎间盘突出症患者椎间融合术后深静脉血栓形成的临床特点及影响因素分析[J]. 中国医学前沿杂志: 电子版, 2018, 10(11): 102-105. 张建陶, 赵斌亮, 郝斌, 等. 利伐沙班与低分子肝素治疗恶性肿瘤并发静脉血栓栓塞症的疗效与安全性分析[J]. 中国药物与临床, 2019, 19(9): 1410-1413. 单文刚, 饶建华, 成旭昱, 等. 低分子肝素预防原发性肝癌切除术后静脉血栓形成的临床观察[J]. 南京医科大学学报: 自然科学版, 2017, 37(5): 593-596 , 631.
潘晓鸿, 汪彩红, 毛敏杰. 低分子肝素钙注射液对重症监护室患者静脉血栓栓塞症的预防作用研究[J]. 中国临床药理学杂志, 2017, 33(1): 74-76. 杜晖, 陈军. 肺癌患者静脉血栓栓塞症的发生及其抗凝治疗[J]. 中国肺癌杂志, 2018, 21(10): 784-789. 吴霞, 崔文宁, 王淑梅, 等. 利伐沙班对急性肺栓塞患者D-二聚体水平及生存质量的影响[J]. 中国实验诊断学, 2018, 22(2): 230-233. -
期刊类型引用(3)
1. 刘锐，刘付昌盛，卢梦月，田智. 慢性阻塞性肺疾病急性加重痰热壅肺证尿液代谢组学研究. 河北中医. 2023(04): 583-588 . 
百度学术
2. 罗燕青，张作清，张昌红. 慢性阻塞性肺疾病患者血清及肺泡灌洗液中CTGF、TGF-β1的水平及意义研究. 国际检验医学杂志. 2018(08): 913-916+921 . 百度学术
3. 许红，刘力，韩彦洁，张瑶. 不明原因复发性流产患者干血斑中多种氨基酸水平分析. 现代医学. 2018(01): 4-6 . 百度学术
其他类型引用(1)
计量
- 文章访问数: 501
- HTML全文浏览量: 151
- PDF下载量: 8
- 被引次数: 4
下载:
苏公网安备 32100302010246号
